Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Allarity Therapeutics Inc ALLR

Healthcare Biotechnology
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs. The company develops drugs for the personalized treatment of cancer using drug specific companion diagnostics generated by its proprietary drug response predictor technology. Its lead drug candidate includes... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ALLR)

Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

GlobeNewswire 2 days ago

Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need

GlobeNewswire February 18, 2026

Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran's Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment

GlobeNewswire February 3, 2026

Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders

GlobeNewswire December 31, 2025

Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates

GlobeNewswire November 14, 2025

Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months

GlobeNewswire September 22, 2025

Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025

GlobeNewswire September 17, 2025

Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer

GlobeNewswire August 26, 2025

Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

GlobeNewswire August 15, 2025
View More News ››

Opinion & Analysis (NDAQ:ALLR)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ALLR)

RE:ALLR ....better than a poke in the eye with a sharp stick

Trading this a.m at $1.77 and starting to gain some traction just broke the RBL trend line....On watch for continuation
Iseneschal - October 9, 2025

ALLR ....better than a poke in the eye with a sharp stick

$1.68
Iseneschal - October 6, 2025

ALLR....started a position this afternoon

$1.61 Cheers !
Iseneschal - September 24, 2025

ALLR....ALLR....ALLR

ALLR....AH AH Lay !!!! I love u
Iseneschal - September 22, 2025

ALLR.....sold all into the a.m strength to H.O.D

I'll be back because the News is good Cheers !
Iseneschal - September 22, 2025

RE:New Press Release - Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months

ALLR is trending higher on this a.m's NR....currently trading over $1.80....the sh price has broken thru the DTL and the next...
Iseneschal - September 22, 2025
View more Bullboard ››

Algernon Health Inc.

Algernon Health Inc.

Algernon Health Inc. operates as a clinical stage pharmaceutical development company in Canada and Australia. The company ...
View More »

Podcasts